Inmed Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of innovative therapies derived from cannabinoids. The company specializes in advancing its proprietary drug development programs, particularly for conditions related to the central nervous system, as well as other unmet medical needs. By leveraging its expertise in cannabinoid-based technology and precision medicine, Inmed aims to address critical health challenges and improve patient outcomes through its unique formulations and delivery methods.
InMed Pharmaceuticals advances INM-901 as an oral treatment for Alzheimer's. Preclinical studies show the small molecule drug achieves effective brain levels, offering a promising alternative to traditional delivery methods.
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all.
When it comes to treating degenerative diseases like Alzheimer’s, much of the current focus is on addressing the symptoms rather than repairing and regenerating the damaged tissues and cells. Some drugs and treatments may slow the progression of cognitive decline, but none can reverse the effects of Alzheimer’s.
